Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2001

View Archived Issues

Allos Therapeutics reports year-end 2000 results, goals for 2001

Status of development programs at OSI

BioTime and Organon Teknika establish exclusive license agreement for Hextend

MicroHeart obtains exclusive license to angiogenic/antiinflammatory compound

Neurocrine reports additional positive clinical results with NBI-34060 for insomnia

Visicol to be copromoted by Procter & Gamble

EntreMed expands phase II 2ME2 program to include prostate cancer

AEterna enters two commercialization alliances for Neovastat in Europe

Adjunctive therapy with rufinamide safe, effective and devoid of significant PK interactions

Antihistaminic equivalence of cetirizine and levocetirizine demonstrated in healthy volunteers

Phase II trial establishes safety and optimal dose of PVAC psoriasis treatment

Potential of PPARgamma agonists in stroke demonstrated in rats using troglitazone

Neuroprotective Ca2+ channel blocker acts by attenuating ischemia-induced glutamate release

Idun presents inhibitors of ICE/ced-3 cysteine proteases

Selective human PPARdelta receptor agonists and their use in type 2 diabetes and related disorders

VLA-4 antagonists with oral activity emerge from Daiichi/Pharmacopeia collaboration

Cytokine inhibitors in the Merck pipeline

New Aventis compounds block Kv1.5 potassium channels

Janssen devotes significant resources to discovery of antiviral agents

Potential new antiulcer agent DBM-819 characterized in vitro and in vivo

Positive hemodynamic results reported in phase III trial of tezosentan

Cyclacel to evaluate lead CDK2 inhibitor in phase I

TMP-substituted phenazine B-4128: antimycobacterial activity and mechanism of action

Akzo Nobel receives offer from bioMerieux for diagnostics business

OP-1 Implant recommended for approval in Australia

Excellent antianaerobic activity demonstrated for BMS-284756

CytRx begins research project with potential treatment for spinal cord injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...